Educational Panel : Immuno-Oncology Milestones to Come: Pipelines Beyond CAR-T 1.0

feb 12, 2018: 9 a.m. - 10:15 a.m.
Salon 2

As the recently approved, initial CAR-T therapies have shown they can produce dramatic improvements for some closely defined patient populations, the next phase of attention shifts to stretching those immuno-oncology (I-O) findings into additional targets, platforms, and indications. These new approaches include allogenic CAR-T products, T-cell regulators, oncolytic viruses, natural killer (NK) cells, and other I-O technologies.  This session will discuss the dynamic opportunities in this space to fight cancer even more effectively.


Moderator: Asthika Goonewardene, Senior Biotechnology Analyst, Bloomberg Intelligence


Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis

Sadik Kassim, PhD, Vice President, Head of Process and Analytical Development, Mustang Bio

Didier Landais, Global Head of Licensing, Servier

Charles Link, MD, Co-Founder, Chairman, CEO, Chief Scientific Officer, NewLink Genetics

Adelene Q. Perkins. Chair and Chief Executive Officer, Infinity Pharmaceuticals

Tito A. Serafini, PhD, President, Chief Executive Officer, and Co-Founder, Atreca, Inc.


Adelene Q. Perkins
Chair and Chief Execut...

Sadik Kassim, PhD
Vice President, Head o...

Asthika Goonewardene
Senior Biotechnology A...

Didier Landais
Global Head of Licensing

Samuele Butera
Global Cell & Gene The...

Tito A. Serafini, PhD
President, Chief Execu...

Charles Link, MD
Co-Founder, Chairman, ...